HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $10

Benzinga · 11/08/2023 13:11
HC Wainwright & Co. analyst Arthur He maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $17 to $10.